Registry-based randomized clinical trials in cardiology: opportunities and challenges
INTRODUCTION The randomized clinical trial (RCT) has become the gold standard for evaluating clinical treatments thanks to its low selection bias and unknown confounders. However, good clinical practice guidelines and demands from regulatory agencies have become so elaborate over time that, basicall...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Permanyer
2021-08-01
|
Series: | REC: Interventional Cardiology (English Ed.) |
Online Access: | https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=625 |
Summary: | INTRODUCTION The randomized clinical trial (RCT) has become the gold standard for evaluating clinical treatments thanks to its low selection bias and unknown confounders. However, good clinical practice guidelines and demands from regulatory agencies have become so elaborate over time that, basically, only big pharmaceutical companies have the resources to conduct large RCTs. Therefore, important questions raised by academic scientists could be impossible to test in clinical trials. |
---|---|
ISSN: | 2604-7322 |